



Washington, D.C. 20231

PUBLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
--------------------	-------------	-----------------------	------------------

08/779, 457 01/07/97 CARTER

ATTY. DOCKET NO.

P P11986P2  
EXAMINER

HM22/0405

ART UNIT	PAPER NUMBER
----------	--------------

GINGER R. DREGER  
KNOBBE, MARTENS, OLSON & BEAR, LLP,  
620 NEWPORT CENTER DRIVE  
SIXTEENTH FLOOR  
NEWPORT BEACH CA 92660

DRAPER,

d4

DATE MAILED:

1646  
04/05/00

is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

## OFFICE ACTION SUMMARY

Responsive to communication(s) filed on Argued for CPA + Amft

is action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 D.C. 11; 453 O.G. 213.

stated statutory period for response to this action is set to expire \_\_\_\_\_ month(s), or thirty days, ever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR a).

## Position of Claims

Claim(s) 133, 40-42 is/are pending in the application.  
All the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
Claim(s) \_\_\_\_\_ is/are allowed.  
Claim(s) 1-23, 40-42 is/are rejected.  
Claim(s) \_\_\_\_\_ is/are objected to.  
Claim(s) \_\_\_\_\_ are subject to restriction or election requirement.

## Specification Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been

 received. received in Application No. (Series Code/Serial Number) \_\_\_\_\_. received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

 Notice of Reference Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_ Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152

-SEE OFFICE ACTION ON THE FOLLOWING PAGES-

\* U.S. GPO: 1996-404-496/40517

Art Unit: 1646

### **Part III: Detailed Office Action**

#### **FORMAL MATTERS**

1. The request filed on 9-28-98 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/779457 is acceptable and a CPA has been established. An action on the CPA follows.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The specification should be amended to refer to the new address for the ATCC depository.

Any objections, rejections, and/or concerns not herein restated have been withdrawn.

3. Applicant's arguments filed 2-2-98 as Paper No 9 have been fully considered but they are not persuasive. See the arguments following the rejection below.

4. *Rejections Over Prior Art:*

Claims 1-33 and 40-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Snodgrass et al. ('748 or '211 or '610)

Snodgrass et al disclose a novel hematopoietin receptor having a WSX motif, which is now known as one form of the Ob/leptin receptor (see the claims). At col 2. Lines 57-59 it is taught that this receptor can be used to screen for ligands or to make antibodies (col 5). While Snodgrass et al did not expressly disclose antibodies to this WSX receptor, or the identity of the ligand as leptin, in view of the fact that the receptor has been identified as a hematopoietin receptor with a WSX motif, it would have been prima facie obvious to use this WSX receptor to make the various claimed antibodies that would possess all of the properties/characteristics of the claims, consistent with the teachings in this prior art that antibodies to the WSX receptor could be made.

Although the claims have been amended to state that the antibodies specifically binds the mature WXS receptor of Seq ID No. 2 (1165 amino acids), which is the Ob or leptin receptor, or

Co b 12-19

Art Unit: 1646

that it binds to a portion of the receptor variant that applicants refer to as 13.2 of Seq Id No. 2, or the antibodies are defined by a deposit number, this rejection is maintained for the reasons of record because the prior art still appears to render the claims *prima facie* obvious. Applicants have argued that the prior art is not enabling according to *In re Payne, Durden & Weiden*, because the prior art only disclosed a partial cDNA clone , which does not enable the full length clone and the resultant use of such to make antibodies that would render the claims *prima facie* obvious. The examiner concedes, as was stated in the first office action, that the prior art did not disclose the full length clone of their hematopoietin receptor; however, this reference is clearly enabling for the full length receptor based on all of the other information provided therein for an obvious method of obtaining the full length receptor transcript that is now known as a form of the human Ob receptor.

It would also appear that part of applicants conclusion is based on the fact that the prior art referred to its receptor as a hematopoietin receptor, namely HuB1.219, whereas the receptors of the instant invention are referred to as Ob receptor. The name of a protein is not binding and, as is well known in the protein art area, the name of a protein is subject to vary drastically or change (and often does) as a result of the specific activity that a particular scientist is studying the protein for, which in many cases have pleiotropic activities-especially for cytokines This is true for many other cytokines and their cognate receptors, and exemplary of such is the instant receptor protein or its cognate ligand, which are referred to as the Ob protein/leptin protein. Another example of this is when earlier work on a protein that regulate body weight was referred to as "Appetite suppression factor", but then the art recognized that this same protein, based on the identifying and synonymous physical features, was the obese or Ob protein. Now most of the art refers to this same protein as leptin. In a similar manner the receptor to this ligand was initially referred to as a hematopoietin receptor, namely HuB1.219, but then the work by others, like that of the instant inventors, referred to their receptor as the Ob receptor, yet others in the art referred to this receptor as the leptin receptor.

Art Unit: 1646

Despite what the receptor is referred to as, it is evident that they are the same receptors, with the exception of the distinct variant forms of this receptor. Conclusive evidence of this comes from the fact that each of the art have recognized that the receptor is a hematopoietin receptor, wherein the receptor has a WSXWS motif that is characteristic of receptors in this Hematopoietin Receptor Superfamily. But more importantly, it is evident that the receptors are the same, despite the different names used to identify it, based on the fact that the sequences that were known and disclosed are substantially the same or overlap (see the 1-569 of Snodgrass et al as compared to residues 114-682 of the human long form as in Seq ID No 4 of the instant application). Applicants have not proffered any comparative evidence in the form of Declaration evidence to prove that the prior art receptor is not the same as the receptor of these claims. Therefore, the name of the receptor protein is not sufficient to identify or characterize a protein, rather it is the physical features such as the molecular weight, the sequence and other physical features that act as the “blue-print or finger-printing” to identify/characterize a protein.

The Examiner position for the obviousness of the full Ob receptor and for the preparation of antibodies to this receptor is clearly **obvious** from Snodgrass et al. For example, Snodgrass et al admits that their sequences represents a partial sequence/partial clone (col 2, line 60, col 3-4, col 15), but based on all of the other teachings, procedures/methods and guidance set forth at col's 3-16, one having ordinary skill in the art would have more than reasonably been able to obtain the full length receptor, including all of the extracellular domain, the transmembrane domain and the cytoplasmic/intracellular domain (col 4, lines 34-39). In fact, cols 3 line 44-51; col 4, line 34+; and col 10, lines 34+ specifically discuss the means and desire for obtaining the full length receptor. Also particularly taught is that various human tissues that were probed to detect for the presence of the receptor yielded the presence of two different size mRNAs, which suggested “that there may be another homologous gene or there is alternatively splicing of a single RNA transcript” (col 15, lines

Art Unit: 1646

18-25). Even though the full length of the receptor was not disclosed, the extremely large portion of the amino acid sequence for the receptor (569 residues as in Seq Id No 3) is overwhelming evidence, in conjunction with the other identifying characteristics such as those set forth at col 15, that the disclosed sequence was in fact a hematopoietin receptor, whose full length could be obtained from the numerous teachings in the patent as cited above.

Contrary to applicant's position, the partial clone for the receptor of the prior art shares more than just a small percent of the identity to the receptor, and even though its full length amino acid sequence is not 100 % disclosed, based on the substantial amount of sequence identity, one skilled in the art would more than reasonably conclude that the human form of the receptor was the same-particularly in view of the fact that the Snodgrass et al patent clearly state that their receptor was a partial clone. Given this teachings, the skilled artisan would have found it obvious to follow the additional teachings of Snodgrass et al in order to obtain the full length transcript for the human hematopoietin receptor, and to make antibodies to this receptor in a manner as taught and for the reasons taught for use of the antibodies.

The 569 amino acids for the human receptor of the prior art corresponds to or is identical residues 114-682 of the instant human long form, which certainly is a sufficient amount of sequence identity for the skilled artisan to reasonable conclude and predict that the receptors are the same, and that the full length receptor (all of the extracellular domain, the transmembrane domain and the intracellular domain) could have been successfully obtained from all of the above listed teachings that are set forth by Snodgrass et al. And even though this prior art was not aware of the fact that their receptor was the Ob-R, and not *certain of the fact* that several variant forms existed, the teachings at col 15, lines 18-25 provided evidence of the possible existence of splice variant, which would have been obvious from using the partial clone of Seq Id No 2 in order to probe a genomic library in order to obtain the full length or other variant forms of the receptor.

Art Unit: 1646

Also argued is that the prior art has not taught how to make agonist antibodies, however, the teachings at col 5 and 6 provide clear motivation for making both agonist and antagonist antibodies from the mature or modified receptor. Even though applicants claims define their antibodies by certain deposit number or designations, antibodies having the same or similar properties to those claimed by applicants would still have been *prima facie* obvious from the prior art based on all of the above evidence.

In the most recent Pre-Amendment to this second CPA, applicants have added a functional limitation for the antibody, but the presence of such does not serve to distinguish this from the prior art. Most of applicants other arguments are consistent with prior arguments and are still not deemed to be persuasive of patentability.

It is believed that all pertinent arguments have been answered.


**5. Advisory Information:**

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to **Garnette D. Draper, Art Unit 1646, whose telephone number is (703) 308-4232**. Examiner Draper can normally be reached Monday through Friday, 9:30 A.M. to 6:00 P.M.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist at telephone number (703) 308-0196.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. **NO DUPLICATE COPIES SHOULD BE SUBMITTED** so as to avoid the processing of duplicate papers in the Office.

**Official papers filed by fax should be directed to (703) 308-4242.** Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. Please advise the Examiner at the telephone number above when an informal fax is being transmitted.

  
GARNETTE D. DRAPER  
PRIMARY EXAMINER  
GROUP 1800